Australia markets open in 1 hour 13 minutes

Biotron Limited (BIT.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0940-0.0030 (-3.09%)
At close: 3:50PM AEST

Biotron Limited

56 Delhi Road
Suite 3.3
North Ryde, NSW 2113
61 2 9805 0488

Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Michelle Miller BSc., GCertAppFin, Ph.D., MSc.CEO, MD & Exec. Director360kN/AN/A
Mr. Peter James Nightingale C.A., B.Econ, CACompany Sec.84kN/A1957
Dr. Stephen L. Becker M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Biotron Limited, a biotechnology company, engages in the developing and commercializing novel small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, including dengue, zika, influenza, ebola, and SARs. Biotron Limited was incorporated in 1999 and is based in North Ryde, Australia.

Corporate governance

Biotron Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.